Aerie Pharma (AERI) Received its Third Buy in a Row

After Mizuho Securities and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Serge Belanger assigned a Buy rating to Aerie Pharma today and set a price target of $26.00. The company’s shares closed last Friday at $9.50, close to its 52-week low of $9.01.

According to, Belanger is a 1-star analyst with an average return of -0.3% and a 38.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Aerie Pharma is a Moderate Buy with an average price target of $24.25, which is a 149.0% upside from current levels. In a report issued on October 20, Oppenheimer also maintained a Buy rating on the stock with a $24.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.26 and a one-year low of $9.01. Currently, Aerie Pharma has an average volume of 720.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts